Issue 25  |   April 2016
ESL Biosciences, in partnership with Euroimmun AG, offer the most comprehensive range of diagnostic products and services for the determination of autoantibodies

Anti-cN-1A (Mup44)

Serological marker for sporadic inclusion body myositis (IBM)

Euroimmun's Anti-cN-1A ELISA offers early and reliable diagnosis of IBM, and allows for differentiation of IBM from other muscle diseases (including polymyositis, dermatomyositis, necrotising myopathy, muscular dystrophy, and myasthenia gravis).  

This kit uses the full length antigen cN-1A (Mup44, NT5C1A).  Euroimmun holds an exclusive worldwide licence for this antigen.  Antibodies against cN-1A are the only known serological marker for inclusion body myositis.

With a 96% specificity rate and the ability to run at room temperature, this ELISA test will often mean fewer muscle biopsies are required.

To order, please use the product code EA 1675-4801.  Contact your local office using the links below for more product information.

If you wish to read more, please take a look at the following papers:
"Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility
Herbert et al, 2015 
"Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis
Pluk et al, 2013
If you are unable to view the full article, please contact us for a copy.

Contact Australia
Contact NZ
Copyright © 2016 ESL Biosciences (Australia) Pty Ltd. All rights reserved.
unsubscribe from this list  |  update subscription preferences